212610-30-5

Upstream product

• 2258-42-6 formyl acetic anhydride 
• 212610-28-1 (2R,3S)-3-(2-tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic acid 
• 6723-30-4 O-2-tetrahydro-2H-pyranhydroxylamine 
• 109053-86-3 methyl (3R)-3-hydroxyhexanoate 
• 212610-24-7 (2R,3R)-2-cyclohexylmethyl-3-hydroxyhexanoic acid 
• 212610-23-6 methyl (2S,3R)-2-(cyclohexylmethyl)-3-hydroxyhexanoate 
• 212610-27-0 Methanesulfonic acid (R)-1-[(R)-2-cyclohexyl-1-(tetrahydro-pyran-2-yloxycarbamoyl)-ethyl]-butyl ester 
• 212610-25-8 (2R,3R)-2-cyclohexylmethyl-3-hydroxyhexanoic acid 2-tetrahydropyranyloxyamide 
• 212610-26-9 (3R,4S)-3-cyclohexylmethyl-4-propyl-1-(2-tetrahydro-2H-pyran-2-yloxy)azetidin-2-one 

Downstream Products

• 260270-92-6 C₂₈H₄₆N₈O₇S 

Relevant academic research and scientific papers

Formamide compounds as therapeutic agents

A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5and R6are as described in the specification, or a pharmaceutica

Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE)

A program to improve upon the in vitro, in vivo, and physicochemical properties of N-hydroxyformamide TACE inhibitor GW 3333 (1) is described. Using the primary structure of pro-TNF-α, along with a homology model of the catalytic domain of TACE based on t